The rationale for this study was to review the data on microalbuminuria (MA), an amount of albumin in the urine of 30-299 mg/day, in patients with diabetes in the context of cardiovascular risk and development of kidney disease. The objective was to review the pathophysiology of MA in patients with diabetes and review the data from trials regarding MA in the context of risk for cardiovascular events or kidney disease progression.
The term "microalbuminuria" (MA) originated in 1964 when Professor Harry Keen first used it to signify a small amount of albumin in the urine of patients with type 1 diabetes (1). The next mention of MA in the literature was 5 years later when Keen et al. (2) examined MA in the context of oral glucose tolerance testing. However, it was not until the late 1970s when Mogensen and Vittinghus (3) and Viberti et al. (4) assessed the effects of insulin treatment on exercise-induced MA and examined albumin excretion in the context of glycemic control. An explosion of studies by these authors and their respective coworkers followed in the 1980s, examining the associations of MA and end-organ injury as well as trying to understand the pathophysiology of MA (5-9).
Almost a half century later, the status of MA has evolved because of insights into the mechanism and associations with disease outcomes. Whereas early research focused on the relevance of MA as a risk factor for diabetic kidney disease, research over the past 2 decades has shifted to examine whether MA is a true risk factor.
To appreciate fully the contribution of MA to overall cardiorenal risk, it is important to distinguish between a risk factor and risk marker. A risk marker is a variable that identifies a pathophysiological state, such as inflammation or infection, and is not necessarily involved, directly or causally, in the genesis of a specified outcome (e.g., association of a cardiovascular [CV] event with fever, high-sensitivity C-reactive protein [hs-CRP], or MA). Conversely, a risk factor is involved clearly and consistently with the cause of a specified event (e.g., a CV event associated with persistently elevated blood pressure or elevated levels of LDL). Both a risk marker and a risk factor can predict an adverse outcome, but only one lies within the causal pathway of a disease. Moreover, a reduction (or alteration in a beneficial direction) of a risk factor (i.e., achievement of blood pressure goal) generally translates into a reduction of adverse outcomes, such as CV events; this is not necessarily true for a risk marker. As we will see, data demonstrating that MA is a risk marker for both CV events and chronic kidney disease (CKD) development in people with and without diabetes have emerged.
Before discussing the studies and the evolution of disease concepts surrounding MA in diabetes, it is also important to note that the terminology of MA has changed recently. The Kidney Disease Improving Global Outcomes group suggested that the term "MA" be replaced by the term "high albuminuria" (10). MA still refers to urinary albumin excretion of 30 to ,300 mg/day as estimated from the urinary albumin-tourinary creatinine ratio (UACR) in a spot morning urine specimen (unadjusted for sex). For the purposes of this discussion, however, we will still use the term "MA." Additionally, to assess for presence of MA, the American Diabetes Association recommends that at least two morning urine specimens collected within 3 months of each other should be abnormal to consider patients as having MA (11).
RESEARCH DESIGN AND METHODS
The data sources included in this article were all PubMed-referenced articles in English-language peer-reviewed journals since 1964. Studies selected had to have a minimum follow-up of 1 year; include at least 100 participants; be either a randomized trial, a systematic review, a meta-analysis, or a large observational cohort study in patients with any type of diabetes; or be trials of high CV risk that included at least 50% of patients with diabetes. All studies had to assess changes in MA tied to CV or CKD outcomes and not purely reflect changes in MA related to blood pressure, unless they were mechanistic studies. On the basis of these inclusion criteria, 31 studies qualified and provide the data used for this review. This review highlights the clinical trials as well as discusses the other studies.
RESULTS

Epidemiology
Early studies in patients with diabetes supported the concept that as MA increases to higher levels, the risk of CKD progression and CV risk also increases (12-14) (Fig. 1) . Moreover, evidence from epidemiological studies in patients with diabetes suggested that the magnitude of urine albumin excretion should be viewed as a continuum of CV risk, with the lower the albumin excretion, the lower the CV risk (15,16). However, MA values can vary daily up to 100% (11). These large biological variations are a result of a variety of conditions, with a central core tied to inflammation associated with factors ranging from increased blood pressure variability, high blood glucose levels, high LDL cholesterol, and high uric acid levels to high sodium ingestion, smoking, and exercise (17) (Fig. 2) . Additionally, any febrile illness, regardless of etiology, will increase urine albumin excretion (18). Taken together, these data support the concept that MA is highly variable and that values over a short time period (i.e., 3-6 months) are meaningless in predicting any CV or kidney disease outcome.
Pathophysiology
Initial studies to understand the mechanisms of MA examined changes in glomerular membrane permeability as a key determinant in patients with diabetes (4, 19) . Many factors affect the genesis and level of MA, most of which are linked to inflammatory conditions (Fig. 2) . A good evidence base, however, supports the concept that MA directly reflects the amount of inflammation and vascular "leakiness" present in patients with diabetes (16, 18, 19) .
More recent studies have found a number of other factors that affect glomerular permeability by modifying cytokines that affect permeability. Increased amounts of glycated albumin reduce glomerular nephrin and increase vascular endothelial growth factor (20). Additionally, increases in sodium intake (21) as well as intraglomerular pressure secondary to high protein intake or poorly controlled blood pressure (22,23) increase glomerular permeability in diabetes and, hence, MA levels.
In individuals with diabetes, albumin is glycated and associated with the generation of reactive oxygen species. In addition, many other factors such as advanced glycation end products, reactive oxygen species, and other cellular toxins contribute to vascular injury. Once such injury occurs, the effect of pressor hormones, such as angiotensin II, is magnified, resulting in a faster progression of vascular injury. The end result is direct injury to the vascular smooth muscle cells, endothelial cells, and visceral epithelial cells (podocytes) of the glomerular capillary wall membrane as well as to the proximal tubular cells and podocyte basement membrane of the nephron (20,24,25). All these contribute to the development of MA.
The magnitude of hyperinsulinemia secondary to insulin resistance is associated with CV risk and higher probability of CV events. The prevalence of MA and level of albuminuria are higher in patients with isolated impaired glucose tolerance than those with impaired fasting glucose (26). However, not all studies confirm an independent association between insulin resistance and MA. A 13-year follow-up study of individuals with long-standing hypertension demonstrated that increases in MA did not predict increased insulin resistance, impaired insulin secretion, or increases in traditional or novel biomarkers of inflammation and endothelial dysfunction. Increases in MA into the macroalbuminuria range were associated with the rate of CKD progression (27). Despite these disparate results, elevated insulin levels are associated with increased vascular inflammation and, hence, the connection with MA regardless of diabetes status (28).
To illustrate the importance of glycemic control on MA development and progression, data from the prospective The most significant insight to date, however, is the finding of a genetic abnormality that predicts MA development. Consequently, there is altered tubular reabsorption of albumin related to cubilin, a proximal tubule receptor protein responsible for albumin reabsorption (33). A metaanalysis of data from 63,153 individuals of European ancestry from genomewide association studies identified susceptibility loci and a missense variant in the cubilin gene (33). Similar associations were noted among 6,981 African Americans (33). This missense variant was associated with a 41% increased risk for persistent MA development over 20 years among 1,304 participants with type 1 diabetes in the DCCT/EDIC study. This 41% risk increase of MA compares with a 10% risk among those without the missense variant (33). Thus, very early in the course of diabetes, the presence of MA would argue for good glycemic control to prevent progression to macroalbuminuria and subsequent CKD progression. Note that MA itself, however, does not indicate the presence of nephropathy.
MA and CV Risk
MA is accepted as a CV risk marker for myocardial infarction and stroke, regardless of diabetes status. Although there is good evidence in those with type 2 diabetes that the presence of MA .100 mg/day is associated with higher CV events and greater likelihood of kidney disease development (6) . Evidence for this association comes from many studies and meta-analyses ( The Heart Outcomes Prevention Evaluation (HOPE) trial provides a strong rationale for MA to be a risk marker for CV disease. Among .9,000 participants in the HOPE trial, the presence of MA increased the relative risk of the primary aggregate end point (myocardial infarction, stroke, or CV death) in those with and without diabetes (1.97 and 1.61, respectively) (39). To further support the concept of MA as a CV risk marker in patients with diabetes the Microalbuminuria, Cardiovascular, and Renal Outcomes (MICRO)-HOPE study demonstrated that the reduction in MA Table 2 ). Consequently, MA may represent either a defect in cubilin, as previously described, or an underlying inflammatory state much like the elevation of hs-CRP reflects inflammation in patients with high CV risk, diabetes, or both.
When albuminuria levels are in the very high or macroalbuminuria range (i.e., .300 mg/day), it is accepted that the patient has CKD and is likely to progress ultimately to ESRD, unless they die of a CV event (39,52). However, only one prospective randomized trial evaluated the role of early intervention to reduce blood pressure with an ACE inhibitor versus a calcium channel blocker in CKD progression by assessing change in MA and creatinine clearance in people with type 2 diabetes (Appropriate Blood Pressure Control in Diabetes [ABCD] trial) (23). After .7 years of follow-up, there was no relationship between changes in MA and CKD progression. Moreover, there was regression to the mean of MA. Blood pressure, however, was well controlled in both treatment groups to levels ,130/80 mmHg (23,53).
Another trial that intervened early in the course of type 2 diabetes to prevent progression based on reduction in MA was the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) (54,55). Like in ABCD, subjects in BENEDICT had diabetes but were normoalbuminuric, but unlike in ABCD, all subjects were hypertensive. The BENEDICT groups were randomized to two different approaches to achieve blood pressure control and followed for 3 years. The primary outcome was development of persistent MA (overnight albumin excretion $20 mg/min at two consecutive visits). After the main trial was completed, a cohort study of those in whom MA developed was followed for another 2 years (55). The primary trial demonstrated that the combination of verapamil and trandolapril was better than verapamil alone for delaying the development of MA. Neither the primary nor the followup trial, however, assessed change in eGFR, so no data are available on CKD outcomes. However, the long-term follow-up showed no difference among an ACE inhibitor, trandolapril alone, or verapamil with the ACE inhibitor on MA reduction or CV events (55). These trials demonstrated an inverse relationship between reductions in MA and primary event rates for CKD or CV events (Tables 1 and 2 ). Moreover, ONTARGET showed that combining therapy of an ACE inhibitor with an ARB not only increased reduction in MA, but also increased the incidence of acute kidney injury. In ONTARGET, the geometric mean of UACR increased from baseline to last observation by 31% (95% CI 26-35%) in groups randomized to ramipril, 24% (95% CI 20-28%) in those randomized to telmisartan, and 21% (95% CI 17-25%) in those randomized to combination therapy. Of those with MA at baseline, progression to very high albuminuria (.300 mg/day) occurred in 2.12% on ramipril, 1.77% on telmisartan, and 1.61% on combination therapy, with a significant difference between those on ramipril versus combination, although CKD outcome (need for dialysis, faster rate of eGFR decline) was worse in the combination group (57).
Many observational studies used development of MA as indicating the presence of early stage CKD. Early studies by the individual groups of Mogensen and Parving demonstrated a relationship between increases in MA and progression to nephropathy in type 1 diabetes. These groups also showed that use of ACE inhibitors, blood pressure reduction, and glucose control reduced MA (9,58,59). However, more recent studies in both type 1 and type 2 diabetes demonstrated that only a subgroup of patients progress from MA to .300 mg/day albuminuria, and this subgroup accounts for those destined to progress to ESRD (29, 32, [60] [61] [62] [63] . Thus, the presence of MA alone is not predictive of CKD progression.
The progressive rise in albuminuria levels associated with nephropathy may relate to genetic susceptibility of nephropathy in a subgroup of patients because an increase in MA is a known marker of nephropathy progression, especially in those with a family history of nephropathy (64) (65) (66) . However, some patients with type 2 diabetes progress to ESRD without ever having developed albuminuria levels of $300 mg/day (67). MA as a marker of nephropathy is a major topic of debate in the nephrology literature. One side contends that MA is a marker of inflammation and higher CV risk and not indicative of kidney disease in people with diabetes (69) , and the other side supports the hypothesis that MA is a clear marker of CKD, even at low levels, regardless of diabetes presence (70) . The arguments against MA as a risk marker for CKD are derived from prospective outcome studies on drugs that block the RAS that focused on time to dialysis, kidney biopsy specimen changes, and doubling of serum creatinine (69) . The side supporting MA as a risk marker for CKD is exclusively based on observational data and post hoc analyses in primarily people without diabetes (70) .
Taken together, data from outcome trials, meta-analyses, and observations demonstrate that MA alone is not synonymous with the presence of clearly defined CKD in diabetes, although it is used as part of the criteria for the diagnosis of CKD in the most recent CKD classification and staging (71) . Note that only a subgroup of ;25-30% of people with diabetes who also have MA will likely progress to more advanced stages of CKD.
Predictors of progression to ESRD, apart from family history, and many years of poor glycemic and blood pressure control are still not well defined. Although there are some genetic markers, such as CUBN and APOL1, their use in practice is not well established. A family history of CKD is a powerful predictor of risk for CKD development and progression in patients with MA. Therefore, all patients should be asked about family history of CKD or members requiring dialysis. Low birth weight is another risk predictor of CKD progression, especially in diabetes, although this is not proven (72) . Additionally, continued increases from MA into the macroalbuminuria range (.300 mg/day) when CV risk factors such as blood pressure, salt intake, and lipids are controlled to target values is most often indicative of progression of underlying CKD, irrespective of its cause.
CONCLUSIONS
Recent advances have allowed us to gain a better understanding of the epidemiology, pathophysiology, and clinical significance of MA among patients with and without diabetes. The current guidelines recommend that MA be assessed annually in all patients with diabetes or CKD (11). Thus, annual measurement of MA should be performed in all patients with diabetes and kidney disease. MA assessment should focus on high-risk patients, such as those who are obese, who are African American, or who have other CV risk factors, including family history of CKD.
In the context of the data presented in this article, MA should be viewed as a risk marker associated with an increase in CV risk and for kidney disease, but its presence alone does not indicate established kidney disease, especially if the eGFR is well above 60 mL/min/ 1.73 m 2 . Increases in MA, with blood pressure and other CV risk factors controlled, are likely but not proven to portend a poor prognosis for CKD progression over time. Achieving target blood pressure (,140/80 mmHg) and target HbA 1c (,7%) should be priorities in treating patients with MA. Recent guidelines from both the American Diabetes Association and the National Kidney Foundation provide a strong recommendation for using agents that block the RAS, such as ACE inhibitors and ARBs, as part of the regimen for those with albuminuria levels .300 mg/ day but not MA (73) . Keep in mind, however, that maximal antialbuminuric effects will not be achieved with these agents unless a low-sodium diet is strictly followed. 
